Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3CI Study: Nivolumab Combination Immunotherapy in CAYA Patients With Relapsed/Refractory Hypermutant Cancers
NCT04500548Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- May 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of nivolumab in cancer (2 arms), sponsored by National Cancer Institute. Primary endpoint: Incidence of adverse events. Planned start May 2021; status: withdrawn.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04500548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04500548.